Avivo enters into know-how agreement with Mayo Clinic for advancement of blood type conversion technology for organ transplants
Avivo is proud to announce a collaboration with Mayo Clinic through a know-how license agreement…
ABOzymes is now Avivo — our new identity for future growth
September 20, 2022 – Avivo means “from life, for life”. This name update reflects the evolution of the company, while maintaining its founding vision: to create a world where blood type is no longer the first constraint in accessing life-saving organ transplants or blood transfusions.
Bruce Cousins, CA
Bruce has more than 30 years life sciences company experience, in both financial and operational roles spanning organizations from large multinational corporations to emerging early phase companies. Currently, Bruce is the President and CFO of Eupraxia Pharmaceuticals (TSX:EPRX). Formerly, he was Executive Vice President & CFO at Arbutus Biopharma (NASDAQ:ABUS) from 2013 to 2018 and CFO of Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV) from 2004 to 2008. Bruce started his life sciences career with Johnson & Johnson (NYSE: JNJ), where, from 1991 to 2004, he worked in a variety of franchises globally including Orthopedics and Wound Closure, completing his tenure with the Wound Management franchise.
ABOzymes completes seed financing round
June 23, 2022 – ABOzymes Biomedical Inc., today announced it has completed a substantially upsized seed financing. The funds will be used to further develop its ground-breaking proprietary platform.
John Coleman, PhD
President & Chief Executive Officer
John is an experienced biotechnology executive who brings more than 20 years of leadership, operational and commercialization experience to Avivo. Most recently, he co-founded and served as Chief Operating Officer, and then President, of Anandia Labs leading to the acquisition by Aurora Cannabis. John also led Project Search for the Centre for Drug Research & Development, now adMare BioInnovations, in which he oversaw that organization’s identification of academic drug discovery projects with exceptional therapeutic potential thus enabling their evaluation and development within CDRD for future commercialization.
ABOzymes Completes Seed Financing Round to Fund Development of Technology to Enable Universal Organ Transplants and Blood Transfusions
June 23, 2022 – ABOzymes Biomedical Inc., announced it has completed a substantially upsized seed financing. The funds will be used to further develop its ground-breaking proprietary platform that enables a world where a patient’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions.
ABOzymes CSO, Peter Rahfeld, recently appeared on the Modern CTO Podcast
May 11, 2022 – Peter Rahfeld, Co-founder & CSO at ABOzymes Biomedical Inc., talks about eliminating the barrier of blood groups and allowing transfusions between all blood types.
ABOzymes awarded $250K in funding through Genome BC’s Pilot Innovation Fund
March 31, 2022 – Genome British Columbia awarded funding to ABOzymes for the ongoing development of a novel process to convert blood group A kidney donor organs to universal blood group O, in a preclinical transplant model with the ultimate objective of meeting the global demand for kidney transplantation.
By altering the blood type of lungs, researchers raise the possibility of universal organs for transplants
February 16, 2022 – Proof-of-concept study demonstrating that human lungs from a type A donor can be treated with the enzymes for a few hours and emerge with the cellular appearance of having O blood type.
ABOzymes is ‘One to Watch’ in Nature’s 2021 Spinoff Prize competition
June 24, 2021 – Nature, the high-impact scientific journal, has listed ABOzymes among its ‘Ones to Watch’ list as part of its international Spinoff Prize competition. This competition highlights start-up companies emerging at universities that are transforming research data into commercial offerings for biomedicine and technology.
Startup of the Week: ABOzymes Biomedical
April 2, 2021 – Switchboard Public Relations spoke to John Barclay, Vice President of Business Development at ABOzymes, about how the entrepreneurship@UBC and New Ventures BC programs helped them along their journey, what the use cases are for their technology and when we can expect to see a world without blood types.
ABOzymes is a Top 10 Finalist in the 2020 New Ventures BC competition!
August 27, 2020 – We are thrilled to announce we have advanced to the Top 10 of this year’s New Ventures BC competition. We’ve completed our pitch to the judges and look forward to the awards ceremony in November.
Type A blood converted to universal donor blood with help from bacterial enzymes
June 10, 2019 – Researchers analyzing bacteria in the human gut have discovered that microbes that produce two enzymes that can convert the common type A into a more universally accepted type. If the process pans out, blood specialists suggest it could revolutionize blood donation and transfusion.
Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs
Donor organ allocation is dependent on ABO matching, restricting the opportunity for some patients to…
An enzymatic pathway in the human gut microbiome that converts A to universal O type blood
Access to efficient enzymes that can convert A and B type red blood cells to…